Cheshire drug company agrees £13m deal with AstraZeneca
Redx Pharma has agreed a $17m (£13m) deal with AstraZeneca that will see the pharmaceutical giant further develop and commercialise a discovery that could aid sufferers of fibrotic diseases.
The Cheshire-based drug development company could receive a further $360m (£280m) in milestone payments from the global licensing deal.
It would also be eligible for tiered royalties of "mid-single digit percentages" for any future net sales.
Redx Pharma chief executive Lisa Anson said the agreement highlighted the company's "ability to... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
